GlassScriptPhysician profile
Latasha Davis
NPI 1891347167
$1,152.57
in general payments reported to CMS, 2019-2025
13 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $106 · 2022: $89.31 · 2023: $362 · 2024: $437 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $956.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $247.95 | 2021-2023 | Arexvy, Bexsero, Pediarix |
| Lilly USA, LLC | $229.67 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $172.39 | 2024-2025 | Otezla, Repatha, Otezla |
| Viiv Healthcare Company | $143.32 | 2021-2024 | Cabenuva |
| Astrazeneca Pharmaceuticals LP | $133.72 | 2024-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $60.52 | 2024 | |
| Shield Therapeutics INC | $41.47 | 2023-2024 | Accrufer |
| Exact Sciences Corporation | $23.51 | 2024 | Cologuard Collection Kit |
| Philips North America LLC | $22.22 | 2022 | |
| Collegium Pharmaceutical, INC. | $20.63 | 2023 | Belbuca |
| Amarin Pharma, INC. | $19.92 | 2021 | |
| Merck Sharp & Dohme LLC | $18.77 | 2021 | |
| Novartis Pharmaceuticals Corporation | $18.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latasha Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.